Stock Research for RGLS

RGLS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RGLS Stock Chart & Research Data

The RGLS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGLS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RGLS Due diligence Resources & Stock Charts

The RGLS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGLS Detailed Price Forecast - CNN Money CNN View RGLS Detailed Summary - Google Finance
Yahoo View RGLS Detailed Summary - Yahoo! Finance Zacks View RGLS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View RGLS Trends & Analysis - Trade-Ideas Barrons View RGLS Major Holders - Barrons
NASDAQ View RGLS Call Transcripts - NASDAQ Seeking View RGLS Breaking News & Analysis - Seeking Alpha
Spotlight View RGLS Annual Report - CompanySpotlight.com OTC Report View RGLS OTC Short Report - OTCShortReport.com
TradeKing View RGLS Fundamentals - TradeKing Charts View RGLS SEC Filings - Bar Chart
WSJ View Historical Prices for RGLS - The WSJ Morningstar View Performance/Total Return for RGLS - Morningstar
MarketWatch View the Analyst Estimates for RGLS - MarketWatch CNBC View the Earnings History for RGLS - CNBC
StockMarketWatch View the RGLS Earnings - StockMarketWatch MacroAxis View RGLS Buy or Sell Recommendations - MacroAxis
Bullish View the RGLS Bullish Patterns - American Bulls Short Pains View RGLS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View RGLS Stock Mentions - StockTwits PennyStocks View RGLS Stock Mentions - PennyStockTweets
Twitter View RGLS Stock Mentions - Twitter Invest Hub View RGLS Investment Forum News - Investor Hub
Yahoo View RGLS Stock Mentions - Yahoo! Message Board Seeking Alpha View RGLS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for RGLS - SECform4.com Insider Cow View Insider Transactions for RGLS - Insider Cow
CNBC View RGLS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGLS - OTC Markets
Yahoo View Insider Transactions for RGLS - Yahoo! Finance NASDAQ View Institutional Holdings for RGLS - NASDAQ


Stock Charts

FinViz View RGLS Stock Insight & Charts - FinViz.com StockCharts View RGLS Investment Charts - StockCharts.com
BarChart View RGLS Stock Overview & Charts - BarChart Trading View View RGLS User Generated Charts - Trading View




Latest Financial News for RGLS


Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Posted on Saturday March 23, 2024

Financial and Clinical Progress Amidst Net Loss Wider Than Estimates


Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Posted on Thursday March 21, 2024

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.


Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Posted on Thursday March 14, 2024

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.


Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Posted on Wednesday March 13, 2024

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.